Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$4.79 USD
-0.16 (-3.23%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.78 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GLUE 4.79 -0.16(-3.23%)
Will GLUE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLUE
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
Other News for GLUE
12 Health Care Stocks Moving In Tuesday's After-Market Session
Monte Rosa Therapeutics management to meet with Piper Sandler
Monte Rosa Therapeutics (GLUE) Initiates Phase 1 Trial for Inflammatory Drug MRT-8102 | GLUE ...
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a ...
Monte Rosa announces first subjects dosed in Phase 1 study of MRT-8102